Perpetual Ltd Sells 19,866 Shares of argenx SE (NASDAQ:ARGX)

Perpetual Ltd decreased its position in shares of argenx SE (NASDAQ:ARGX) by 14.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 120,914 shares of the company’s stock after selling 19,866 shares during the period. Perpetual Ltd’s holdings in argenx were worth $74,362,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Point72 Hong Kong Ltd bought a new position in shares of argenx in the 2nd quarter valued at $76,000. Cromwell Holdings LLC boosted its stake in argenx by 73.3% in the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after buying an additional 66 shares in the last quarter. GAMMA Investing LLC boosted its stake in argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock valued at $94,000 after buying an additional 56 shares in the last quarter. Blue Trust Inc. grew its position in argenx by 413.9% in the third quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after acquiring an additional 298 shares during the last quarter. Finally, Keudell Morrison Wealth Management acquired a new position in argenx during the third quarter worth about $207,000. 60.32% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ARGX has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $717.00 price target (up from $670.00) on shares of argenx in a research note on Tuesday, January 14th. William Blair upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a research report on Friday, November 1st. Piper Sandler upped their price target on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a report on Tuesday, January 7th. Wolfe Research upgraded argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price target for the company in a research note on Tuesday, November 12th. Finally, JPMorgan Chase & Co. boosted their price objective on argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $658.39.

argenx Stock Down 2.9 %

NASDAQ:ARGX opened at $640.52 on Tuesday. argenx SE has a 52 week low of $349.86 and a 52 week high of $678.21. The firm’s fifty day moving average is $621.22 and its 200-day moving average is $558.80.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $588.88 million for the quarter, compared to analysts’ expectations of $543.29 million. During the same quarter in the prior year, the firm posted ($1.25) earnings per share. On average, research analysts forecast that argenx SE will post 2.51 earnings per share for the current year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.